Valued at a market cap of $28 billion, San Diego, California-based DexCom, Inc. (DXCM) is a medical machine firm that focuses on the design, improvement, and commercialization of steady glucose monitoring (CGM) methods for the administration of diabetes and metabolic well being in america and internationally.
Firms with a market cap of $10 billion or extra are usually known as “big-cap shares.” DXCM suits squarely into that class, with its market cap exceeding this threshold and reflecting its substantial measurement and affect within the medical units business.
Extra Information from Barchart
Nonetheless, DXCM inventory is down 19.3% from its 52-week excessive of $89.98 touched on July, 30. Furthermore, DXCM declined marginally over the previous three months and has lagged behind the Dow Jones Industrial Common ($DOWI), which rose 5.8% throughout the identical interval.
Zooming out somewhat additional, the state of affairs stays the identical. Over the previous 52 weeks, DXCM has declined 15.2%, underperforming DOWI’s 21.5% acquire.
DXCM has been buying and selling above its 200- and 50-day shifting averages since final month, indicating bullish momentum.
On Apr. 30, DXCM inventory rose 3.5% following the discharge of its Q1 2026 earnings. The corporate’s income for the quarter amounted to $1.2 billion and surpassed the Road’s estimates. Furthermore, its adjusted EPS for the interval got here in at $0.56, additionally topping Wall Road’s forecasts. DexCom expects full-year income within the vary of $5.16 billion to $5.25 billion.
When stacked towards its peer, GE HealthCare Applied sciences Inc. (GEHC), DXCM has underperformed. Over the previous 12 months, GEHC inventory has declined 10.3%.
Nonetheless, sentiment on DXCM stays extremely optimistic. Among the many 27 analysts protecting the inventory, the consensus ranking is a “Robust Purchase.” Its imply worth goal of $81.58 suggests 12.4% upside from present ranges.
On the date of publication, Aritra Gangopadhyay didn’t have (both instantly or not directly) positions in any of the securities talked about on this article. All data and information on this article is solely for informational functions. This text was initially printed on Barchart.com